Anticorps Recombinant de lapin anti-MOG

MOG Recombinant Antibody for WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, porc, rat, souris

Applications

WB, ELISA

Conjugaison

Non conjugué

CloneNo.

250235E1

N° de cat : 83063-6-RR

Synonymes

MOGIG 2, Myelin-oligodendrocyte glycoprotein



Applications testées

Résultats positifs en WBtissu cérébral de souris, tissu cérébral de porc, tissu cérébral de rat

Dilution recommandée

ApplicationDilution
Western Blot (WB)WB : 1:5000-1:50000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

83063-6-RR cible MOG dans les applications de WB, ELISA et montre une réactivité avec des échantillons Humain, porc, rat, souris

Réactivité Humain, porc, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène MOG Protéine recombinante Eg2878
Nom complet myelin oligodendrocyte glycoprotein
Masse moléculaire calculée24 kDa
Poids moléculaire observé 25-28 kDa
Numéro d’acquisition GenBankN/A
Symbole du gène MOG
Identification du gène (NCBI) 4340
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.02% sodium azide and 50% glycerol
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Myelin/oligodendrocyte glycoprotein (MOG), a 23~28 kDa glycoprotein, a myelin antigen at the outer surface of the central nervous system (CNS) myelin sheath, which may trigger T-cell as well as B-cell responses. It therefore constitutes a pivotal target for autoimmune responses, which result in inflammation and also demyelination in the CNS. Its presence on the outer- most lamellae of mature CNS myelin and its late appearance during myelinogenesis suggest that it contributes to myelin maturation or maintenance. 10 isoforms of MOG produced by alternative splicing have been described, and heterodimers may be formed between the different isoforms. Defects in MOG are the cause of narcolepsy type 7 (NRCLP7), a neurological disabling sleep disorder characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement (REM) sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis. Role of MOG in the pathogenesis of multiple sclerosis (MS) has been reported but remains to be clarified.

Protocole

Product Specific Protocols
WB protocol for MOG antibody 83063-6-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}